Xspray Pharma Q4 2022: Very Eventful Months Ahead - Redeye

Redeye leaves comments on Xspray following its Q4 2022 report, which left updates on the commercialization strategy of XS004 and also announced the RLD of XS008. The company stands before a very exciting year, and we will return shortly with an extended research update on the company where we adjust our valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/881409/xspray-pharma-q4-2022-very-eventful-months-ahead?utm_source=finwire&utm_medium=RSS